Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $99.18 Analyst target: $121.67 Upside: 22.68%
Kodiak Sciences Inc., a clinical-stage biopharmaceutical company, is dedicated to researching, developing, and marketing therapies to treat retinal diseases in the United States and international markets. The company is headquartered in Palo Alto, California.
See the full interactive analysis & chart →Informational only — not investment advice.